Despite a few hiccups recently in partnered/out-licensed programs, Alnylam (ALNY) recently announced another clinical win for its ATTR amyloidosis program, and the company moves into 2021 with three approved products, a fourth soon to come, and a deep pipeline that the company discussed in more detail during a two-day R&D event back in December.
Alnylam had a respectable 2020 from a market performance standpoint, but couldn’t keep pace with the broader biotech sector. With 2021 looking a little light in terms of thesis-changing events, it could be a little harder to maintain the momentum, but I do believe the pipeline and commercial opportunities support a fair value in the mid-$160’s.
Read the full article here:
Alnylam Pharmaceuticals Logs Another Clinical Win For Its Amyloidosis Program
No comments:
Post a Comment